Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Genor Biopharma Holdings Limited ( (HK:6998) ) is now available.
Genor Biopharma Holdings Limited announced that the China National Medical Products Administration has approved the new drug application for Lerociclib (GB491), a treatment for HR+/HER2- locally advanced or metastatic breast cancer. This approval marks a significant milestone for the company, highlighting its successful collaboration with G1 Therapeutics Inc. and demonstrating the effectiveness of its cross-functional teams in advancing cancer therapies.
More about Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. It focuses on developing innovative therapies, particularly in the field of oncology, with a market focus on advanced breast cancer treatments.
Average Trading Volume: 724,365
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.44B
Find detailed analytics on 6998 stock on TipRanks’ Stock Analysis page.